The QualityStocks Daily Wednesday, September 4th, 2019

Today's Top 3 Investment Newsletters

QualityStocks (CELZ) +100.00%

SmallCapRelations (NTRR) +26.09%

PennyStockProphet (OPGN) +23.01%

The QualityStocks Daily Stock List

Canacol Energy Ltd. (CNNEF)

Zacks, Stock Muse, StreetWise Reports, Morningstar, TradingView, GlobeNewswire, InvestorsHub, Wallet Investor, Stockhouse, TMXmoney, Investing.com, and Market Screener reported previously on Canacol Energy Ltd. (CNNEF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Canacol Energy Ltd. mainly explores for, develops, and produces petroleum and natural gas in Colombia. It is a leading natural gas exploration and production company in Colombia. As of December 31, 2018, the Company has a total proved plus probable reserves of 98,050 one thousand barrels of oil equivalent. Canacol Energy’s shares trade on the OTC Markets Group’s OTCQX. The Company has its head office in Calgary, Alberta.

Recently, Canacol Energy announced that the works associated with the expansion of the gas pipeline between its operated Jobo gas processing facility and Cartagena has been completed. The works included the laying of 85 kilometers of 20 inch pipeline and the installation of additional compression. This resulted in an increase of 100 MMscfpd of transportation capacity for the Company to its clients in Cartagena.

Last week, Canacol Energy announced that it achieved a record 217 million standard cubic feet per day (MMscfpd) (38,070 barrels of oil equivalent per day) of natural gas sales on August 24, 2019. This level of sales was realized in part through the recently announced completion of the pipeline expansion between the Corporation’s gas processing facilities situated at Jobo and the City of Cartagena at the end of July 2019. Canacol Energy anticipates that it will maintain an average gas sales level of roughly 215 MMscfpd for the remainder of this year.

Mr. Charle Gamba, President and Chief Executive Officer of Canacol Energy, stated, “We are very pleased to have achieved this historic level of gas sales which places Canacol as the largest independent producer of natural gas in Colombia. We have demonstrated how the decline of gas production in Colombia can be reversed through a combination of exploration and the construction of new gas pipeline infrastructure. Production levels from our gas fields have now surpassed, and are replacing, production from the declining gas fields located in Guajira.”

Canacol Energy Ltd. (CNNEF), closed Wednesday's trading session at $3.64, up 0.831025%, on 23,050 volume with 36 trades. The average volume for the last 3 months is 29,369 and the stock's 52-week low/high is $2.63000011/$3.96000003.

chart

Rokk3r, Inc. (ROKK)

OTC Markets, Stockwatch, Street Insider, Stockhouse, Biz Journals, MarketWatch, PR Newswire, GlobeNewswire, Simply Wall St, Lat10k, Stockopedia, and Market Screener reported beforehand on Rokk3r, Inc. (ROKK), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Rokk3r, Inc. provides consulting services and related value generating strategies through a technology platform. The Company is a global idea-to-exit company builder and consulting services enterprise. The design of its services are to leverage exponential technologies to quickly accelerate and shape industries. Rokk3r has operations in three continents. It has built and funded greater than 40 companies. More than 160 ideas have been exponentiated.

The Company formerly went by the name Eight Dragons Company. It changed its name to Rokk3r, Inc. in March 2018. Rokk3r has its corporate office in Miami, Florida.

Rokk3r provides a set of services that is a hybrid network of human and machine intelligence systems, seeking to enable early stage start-up technology companies and existing businesses to develop new products and businesses in a frictionless, accelerated and complete manner. These exponential technologies include artificial intelligence (AI), augmented and virtual reality (AR, VR), blockchain (decentralized ledger technologies), data science, digital biology and biotech, machine learning, nanotech, robotics, and sensors.

Rokk3r’s ecosystem approach reduces friction and streamlines execution through taking advantage of talent, shared services, experience, and networks. The Company offers business diagnosis to strategy design, execution and funding. Its expertise is in Blockchain, AI, IoT (Internet of Things), and Big Data for the FinTech (Financial Technology), Digital Marketing, PropTech, and Industry Services sectors.

Rokk3r has acquired Bullfrog Ventures. Bullfrog was founded in 2016 to hasten the transition of insurance solutions to be more predictive and preventive, lessening material damages and improving people's lives. Bullfrog Ventures’ Insurtech Portal, in partnership with Chubb Latin America, includes more than 80 Insurtechs. Bullfrog's Insurtech platform includes 16 curated insurtechs from all over the world.

Today, Rokk3r announced that Company Chief Marketing Officer, Andrea Arnau, will star in the upcoming season of the hit TV show "Shark Tank Colombia." The show's latest installment will kick off on September 6, 2019 at 10 p.m. (GMT-5), on Canal Sony. Arnau will be among eight investors on the Colombian adaptation of the TV show, including energy sector businessman Frank Kanayet; experiential marketing guru Ricardo Leyva Gutiérrez; Samy Bessudo, president of Colombia's largest travel agency; and financier Alejandra Torres.

Rokk3r, Inc. (ROKK), closed Wednesday's trading session at $0.9525, even for the day. The average volume for the last 3 months is 4,858 and the stock's 52-week low/high is $0.497500002/$4.00.

chart

Cresco Labs, Inc. (CRLBF)

New Cannabis Ventures, CannabisMarketCap, Pot Stock News, Profit Confidential, Midas Letter, TipRanks, NIC Investors, Equities, Investopedia, Market Screener, Technical420, Green Market Report, TMXmoney, Wallet Investor, Stockwatch, TradingView, and Stockhouse reported earlier on Cresco Labs, Inc. (CRLBF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cresco Labs, Inc. is one of the largest vertically integrated multi-state cannabis operators in the U.S. The Company employs a consumer-packaged goods (CPG) approach to cannabis. The design of its family of brands is to meet the needs of all consumer segments. Its products are sold in more than 700 dispensaries across the nation. Cresco has 22 owned dispensaries. Cresco Labs lists on the OTC Markets Group’s OTCQX. The Company has its head office in Chicago, Illinois.

Cresco Labs’ brands include some of the most recognized and trusted national brands including Cresco, Remedi and Mindy’s, a line of edibles created by James Beard Award-winning chef Mindy Segal. Sunnyside is the Company’s national dispensary brand. Sunnyside is a wellness-centered retailer designed to build trust, education, and also convenience for existing and new cannabis consumers.

Cresco Labs is a vertically integrated cannabis company. It controls its cultivation, manufacturing, extraction and packaging practices. It is involved at every point in the seed-to-sales process. The Company’s facilities are powered by world-class agronomists, manufacturing experts and state-of-the-art agricultural equipment. Cresco packages, ships, and distributes its products nationwide, including locations owned and operated by its team.

Last month, Cresco Labs announced that it received regulatory approval for its acquisition of 100 percent of the membership interests of Gloucester Street Capital, LLC, the parent entity of Valley Agriceuticals, LLC (Valley Ag) through a merger between Gloucester and an indirect subsidiary of Cresco Labs. Valley Ag holds one of the 10 vertically integrated cannabis business licenses granted in the State of New York by the New York State Department of Health. Each license gives the operator the right to operate one cultivation facility and four dispensaries in New York. Recently, Valley Ag’s license was renewed for a two-year period.

Mr. Charles Bachtell, Chief Executive Officer and Co-founder of Cresco Labs, said, “We are very pleased to take the next step in building the most strategic and valuable geographic footprint in the cannabis industry. As the holder of one of only 10 vertically integrated businesses licenses in New York, we believe that Cresco Labs will make a significant impact in this large and influential market that is projected to grow to $500 million by 2022, according to Arcview/BDS Analytics.”

For Q2 2019, Cresco Labs had Revenue of $29.9 million. This is up 253 percent year-over-year and 42 percent quarter-over-quarter. Q2 pro forma Revenue increased 55 percent quarter-over-quarter to $52.7 million. This includes the impact of pending acquisitions and investments.

Cresco Labs, Inc. (CRLBF), closed Wednesday's trading session at $8.842, up 5.2619%, on 222,943 volume with 619 trades. The average volume for the last 3 months is 224,402 and the stock's 52-week low/high is $4.18588018/$14.3900003.

chart

Gungnir Resources, Inc. (ASWRF)

Stock Minute, Junior Mining Network, Northern Miner, EODData, Market Screener, Big News Network, Dividend Investor, Wallet Investor, GlobeNewswire, TradingView, Proactive Investors, Morningstar, TMXmoney, 4-Traders, Investors Hangout, InvestorsHub, Morningstar, Nasdaq, and Stockhouse reported previously on Gungnir Resources, Inc. (ASWRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Gungnir Resources, Inc. is a mineral exploration company with gold and base metal permits in northern Sweden. Gungnir holds gold and base metal exploration permits in Sweden’s prolific Vasterbotten District which hosts 12 million ounces of gold delineated in existing and mined resources plus several past-producing and producing volcanogenic massive sulphide (VMS) base metal mines. Gungnir Resources has its corporate office in Surrey, British Columbia.

The Company previously went by the name Anglo Swiss Resources, Inc. It changed its name to Gungnir Resources, Inc. in June of 2014. In 2017 and 2018, successful drill programs at Gungnir Resources’ Knaften project resulted in back-to-back new base metal target discoveries; the Rodingtrask VMS and an adjacent Cu-Ni target. These new targets add considerable upside to the previously gold-only Knaften project. At present, Gungnir Resources has many opportunities at deposit discovery via manifold targets and metals. All three targets on Knaften are wide-open for expansion and further discovery.

Gungnir Resources’ key emphasis is the Knaften project positioned at the south end of the “Gold Line” (Knaften-Barsele Arc) that hosts several gold deposits including Faboliden and Svartliden (Dragon Mining), and the Barsele Gold-VMS project (Agnico Eagle). Of note is that Sweden is the leading mining nation in Europe. Sweden continues to receive high institute rankings as one of the top countries in the world for exploration and mining.

Last week, Gungnir Resources announced that it drilled two mineralized structures at its Knaften 300 Gold Zone (Knaften 300) in Sweden. Three holes, KN19-06, -07 and -08, each cut two main zones of arsenopyrite mineralization, which is the key indicator of gold mineralization at Knaften 300. Drilling is continuing to test grade and continuity of these mineralized zones.

Jari Paakki, Gungnir Resources’ Chief Executive Officer, said, "This appears to be an important development as we are starting to see predictive structural controls on arsenopyrite, the key indicator of gold mineralization on the property. We are postulating a thrust-fault model which we think will help us systematically expand Knaften 300 and further, it opens up the possibility of additional stacked zones (mineralized thrust faults) at depth and in the western part of the Knaften property. We eagerly await assays from these three holes.”

Gungnir Resources, Inc. (ASWRF), closed Wednesday's trading session at $0.08, off by 11.0122%, on 17,900 volume with 5 trades. The average volume for the last 3 months is 20,865 and the stock's 52-week low/high is $0.037399999/$0.292400002.

chart

Intrinsyc Technologies Corporation (ISYRF)

TeleTrader, InvestorX, Ceo.ca, 4-Traders, Virtual-Strategy.com, PortfolioSharing, PR Newswire, Stockhouse, Stockwatch, Wallet Investor, MarketBeat, and InvestorFile reported beforehand on Intrinsyc Technologies Corporation (ISYRF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Intrinsyc Technologies Corporation is a top provider of solutions for the development of embedded and Internet of Things (IoT) products. It provides comprehensive product development services, as well as the industry’s highest-performance edge computing modules, to enable quick commercialization of intelligent IoT products. Intrinsyc Technologies has its corporate office in Vancouver, British Columbia. The Company lists on the OTC Markets’ OTCQX.

Intrinsyc Technologies partners with the world’s foremost OEMs (original equipment manufacturers) to create award-winning products. These include consumer mobile devices and embedded and IoT applications such as robotics, wearables, automotive, medical, video conferencing, digital signage, industrial and consumer cameras, and many more.

Intrinsyc Technologies provides hardware, software, and services that enable next-generation intelligent connected products. The Company’s solutions cover the entire development life cycle. Its solutions help device makers and technology suppliers create differentiated products with speedier time-to-market. Intrinsyc offers a portfolio of embedded computing modules based on Snapdragon™ technology from Qualcomm® Technologies, Inc., and i.MX processors from NXP Semiconductors N.V.

Last month, Intrinsyc Technologies announced the signing of a supply agreement and receipt of an order valued at US$1,195,000. The initial stocking order is for the purchase of the Company’s Open-Q™ 835 edge AI (Artificial Intelligence) computing modules to be used in a next-generation video collaboration product. The expectation is that delivery will occur in Q4 2019.

In August, Intrinsyc Technologies announced its financial results for Q2 ended June 30, 2019. The Company achieved Revenue of US $5.5 million (CDN $7.3 million) with EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of US $169,429 (CDN $226,644). It achieved its most productive quarter ever with 9 new design wins. In addition, Intrinsyc achieved its most productive quarter of new product introductions with the launch of four new Edge AI computing platforms.

This past May, Intrinsyc Technologies announced the Open-Q™ 212A SOM and Development Kit. The Open-Q™ 212A SOM is a compact (50mm x 46.5mm) pre-certified, production-ready embedded computing module. It is ideal for cost-sensitive home hub, home automation, and smart audio devices featuring voice control, AI, and wireless connectivity. It is powered by the Qualcomm® Home Hub 300 Platform based on the Qualcomm® APQ8009 System-on-Chip (SoC).

Intrinsyc Technologies Corporation (ISYRF), closed Wednesday's trading session at $0.8216, off by 0.170109%, on 2,300 volume with 2 trades. The average volume for the last 3 months is 805 and the stock's 52-week low/high is $0.80489999/$1.25997996.

chart

Item 9 Labs Corp. (INLB)

CannabisMarketCap, Market Screener, Stockwatch, Street Signals, Stocks Beat, Street Insider, Pot Stock News, Nasdaq, InvestorsHub, Morningstar, TradingView, OTC Markets, and TipRanks reported earlier on Item 9 Labs Corp. (INLB), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Item 9 Labs Corp. is a leader in comfortable cannabis health solutions for the contemporary consumer. Its asset portfolio includes Dispensary Permits, Dispensary Templates, and Strive Life. The Company is also advancing the industry with its product suites. Item 9 Labs has created complementary brands - Item 9 Labs and Strive Wellness - to channel consumer diversity. The Company is based in Phoenix, Arizona.

Item 9 Labs is bringing best of industry practices to markets from coast to coast. It is doing so through cultivation and production, distinctive retail environments, licensing services, and diverse product suites catering to different medical cannabis demographics. Its Dispensary Permits is its consulting firm. It specializes in strategic license application and compliance.

The Dispensary Templates subdivision is a technology platform with a comprehensive digital library of licensing and business planning resources. Moreover, Strive Life is a turnkey dispensary model for the retail sector. It enhances the patient experience with consistent and premier service, high-end design, as well as precision-tested products. Currently, Strive Life is undergoing implementation in Arizona and North Dakota.

Item 9 Labs’ propriety delivery platforms include the Apollo Vape and Pod system, and an inventive intra-nasal device. The Company’s intention is to manage cultivation, processing, distribution, and dispensary operations in up to ten U.S. markets by the end of 2019. Current facilities include distribution and processing operations Strive Wellness of Ohio and Strive Wellness of Nevada, and dispensary Strive Life North Dakota.

Item 9 Labs announced its expanded Arizona cultivation and manufacturing facility received State approval to operate. The custom 10,000 square-foot construction passed inspections on June 4, 2019. It started production the week of June 10, 2019.

Recently, Item 9 Labs announced the launch of its new product suite, “Cocktails”. This is an innovative first to market disposable vape pen with cartridge and battery inspired by popular culture’s classic aperitifs. The Company’s mixology team developed the craft-cannabis line using organic fruit, botanically-derived terpenes, and 100 percent solvent-free distillate.

The long-lasting disposable Cocktails vape pen is supplemented by a charging port for those patients who medicate less frequently. “Cocktails’ comes with 300 mg. of premium distillate in four signature flavors. These are Blackberry Mojito, Piña Colada, Old Fashioned, and Strawberry Daiquiri.

Last week, Item 9 Labs announced it is a Fully Reporting Company with the U.S. Securities and Exchange Commission (SEC) now that its Form 10 Filing became effective. The Company is now subject to the reporting requirements of the Exchange Act of 1934, as amended.

For the three months ending June 30, 2019, versus the three months ending June 30, 2018, Item 9 Labs’ Revenue increased 251 percent to $1,542,067. Operating Margins increased to 55 percent from 14 percent. Pre-tax earnings of the Company’s operating entities totaled $491,553. Net loss was $864,176. Diluted loss per Share was $.01.

Item 9 Labs Corp. (INLB), closed Wednesday's trading session at $3.00, even for the day, on 922 volume with 4 trades. The average volume for the last 3 months is 2,288 and the stock's 52-week low/high is $1.50/$8.39999961.

chart

Lixte Biotechnology Holdings, Inc. (LIXT)

InvestorsHub, Morningstar, Stockopedia, Dividend Investor, Wallet Investor, Street Insider, PR Newswire, Small Cap Network, Market Screener, 4-Traders, YCharts, OTC Markets, Simply Wall St, Last10k, MarketBeat, and Stockhouse reported previously on Lixte Biotechnology Holdings, Inc. (LIXT), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. It uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. Its product pipeline is primarily centered on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or X-ray and immune checkpoint blockers. A clinical-stage pharmaceutical company, Lixte Biotechnology Holdings is headquartered in East Setauket, New York. The Company lists on the OTCQB.

Lixte Biotechnology has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The Company’s present drug portfolio includes inhibitors of serine/threonine protein phosphatases critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.

The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general and radiation therapy. This makes them potentially useful for the treatment of manifold cancers in combination with existing standard chemotherapy regimens and with the developing targeted cytotoxic therapies of personalized cancer medicine.

Furthermore, in a pre-clinical study done with scientists under collaborative research and development agreements at the National Institutes of Health, Lixte’s lead compound, LB-100, enhanced the antitumor activity of a major immune checkpoint inhibitor. Consequently, this raises the possibility that in addition to improving the efficacy of standard cytotoxic anti-cancer drugs, Lixte’s phosphatase inhibitors may potentiate immunotherapy regimens (Ho 2017).

Recently, Lixte Biotechnology announced that the first patient has been enrolled in its Phase 1b/2 study of the safety and therapeutic benefit of the Company’s lead clinical compound, LB-100, in patients with low and intermediate-1 risk myelodysplastic syndrome (MDS) who have failed or are intolerant of standard treatment (NCT03886662). This study is open at Moffitt Cancer Center in Tampa, Florida. Dr. Rami Komrokji, Vice Chair of Moffitt’s Department of Malignant Hematology, is the principal investigator.

In August, Lixte Biotechnology announced that it signed a clinical trial agreement with the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, GEIS). This agreement is to support a Phase 1b/randomized Phase 2 study of doxorubicin, the international standard for the initial treatment of advanced soft tissue sarcomas (ASTS), in comparison to doxorubicin plus LB-100.

Lixte Biotechnology Holdings, Inc. (LIXT), closed Wednesday's trading session at $1.35, even for the day, on 1,150 volume with 2 trades. The average volume for the last 3 months is 1,928 and the stock's 52-week low/high is $0.600000023/$1.45000004.

chart

CipherLoc Corporation (CLOK)

NetworkNewsWire, StreetWise Reports, Penny Stock Tweets, Street Insider, Morningstar, Stockhouse, OTC Markets, Marketbeat, The Street, and Stockwatch reported previously on CipherLoc Corporation (CLOK), and we also report on the Company, here at the QualityStocks Daily Newsletter.

A data security solutions company, CipherLoc Corporation provides highly secure, quantum-safe data protection technology. Its highly innovative solutions are founded on its patented Polymorphic Cipher Engine. The design of this is to enable an ironclad layer of protection to be added to existing products, services, or applications. OTCQB-listed, CipherLoc has its head office in Buda, Texas.

The Company delivers solutions that are highly secure, synergistic, as well as scalable. CipherLoc’s mission is to keep information safe and it makes encryption quicker, stronger, and scalable.

The Company’s unique and patented polymorphic technology eliminates the flaws and inadequacies associated with today’s encryption algorithms. Instead of dealing with large monolithic blocks of data, the patented CipherLoc approach decomposes the information to be protected into numerous segments.

The individual segments each have a unique encryption key, use different encryption algorithms, are randomly grouped into different lengths, and can be further re-encrypted. Segments are independent from each other and are individually protected. Thus, the CipherLoc technology is not susceptible to computational attacks.

Recently, CipherLoc announced the signing of its first commercial license agreement with SoundFi, a pioneering "app based" audio technology platform delivering premium 360-degree sound via headphones "in movie theaters", for a personalized audio experience. SoundFi offers in-theater and streaming content experiences for consumers. SoundFi has signed an agreement to license CipherLoc's encryption engine products to keep SoundFi's movie soundtracks secure and safe.

CipherLoc also recently announced its Cipherloc Secure Messenger application, offering comprehensive data protection for text messaging, voice and video calls on mobile devices. The initial release is expected early summer. It will support text messaging, with secure end-to-end voice and video calls available soon thereafter. The new solution is built upon the Company’s patented data protection technology. It will allow users to communicate with each other in complete privacy via end-to-end encryption.

Cipherloc has also announced the appointment of Mr. Tom Wilkinson as an Independent Director effective May 21, 2019. In addition, Mr. Wilkinson will form and chair the Audit Committee of the Board of Directors. He brings a background in public accountancy and C-level executive experience for a Nasdaq listed company to CipherLoc. He currently owns and operates Wilkinson & Company, which is a financial and business consulting firm centered on emerging growth pre-IPO (Initial Public Offering) and public companies.

CipherLoc Corporation (CLOK), closed Wednesday's trading session at $0.749, up 24.8333%, on 8,790 volume with 11 trades. The average volume for the last 3 months is 8,089 and the stock's 52-week low/high is $0.50999999/$2.3499999.

chart

Cardax, Inc. (CDXI)

Zacks, Street Insider, The Street, 4-Traders, Stockopedia, Morningstar, InvestorsHub, Market Exclusive, MarketWatch, GuruFocus, last10k, Barchart, Stockhouse, and Street Insider reported earlier on Cardax, Inc. (CDXI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cardax, Inc. is a development stage Life Sciences Company listed on the OTCQB. It dedicates primarily all its efforts to developing consumer health and pharmaceutical products that it believes will provide many of the anti-inflammatory benefits of steroids or NSAIDS through targeting many of the same inflammatory pathways and mediators, however with exceptional safety profiles. Cardax has its corporate headquarters in Honolulu, Hawaii.

The Company is preparing proprietary nature-identical products and related derivatives via total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated. This includes, but is not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease.

Cardax’s initial main focus is its astaxanthin technologies. Astaxanthin is a strong and safe, naturally occurring, anti-inflammatory and anti-oxidant without the adverse side effects characteristic of anti-inflammatory treatments using steroids or NSAIDS (including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding).

The Company’s ZanthoSyn® is its first product to help consumers safely address their inflammatory health. Cardax says that ZanthoSyn® is a physician recommended, anti-inflammatory supplement for health and longevity that features astaxanthin with optimal absorption and purity. ZanthoSyn® contains astaxanthin, which is Generally Recognized as Safe (GRAS) according to Food and Drug Administration (FDA) regulations. The safety and efficacy of the Company’s product candidates have not been directly evaluated in clinical trials or confirmed by the FDA.

Recently, Cardax announced it launched its Cardiovascular Health Astaxanthin Supplement Evaluation (CHASE) clinical trial targeting cardiovascular inflammatory health. The first subject was dosed on September 19, 2018. This randomized, double-blind, placebo-controlled CHASE clinical trial will evaluate the effect of low-dose and high-dose ZanthoSyn® on cardiovascular health, as measured by C-Reactive Protein (CRP) levels, over 12 weeks in up to 360 subjects with documented cardiovascular risk factors. Additionally, the study will include an optional open label extension through 48 weeks.

Cardax and GNC also recently announced that they are expanding the sales and marketing program for ZanthoSyn®. GNC is the exclusive brick-and-mortar retail channel for ZanthoSyn®. GNC will augment Cardax's sales and marketing efforts with additional initiatives to boost ZanthoSyn® product awareness and education among GNC store associates and customers nationwide.

Cardax, Inc. (CDXI), closed Wednesday's trading session at $0.1279, up 27.9%, on 100 volume with 1 trade. The average volume for the last 3 months is 20,175 and the stock's 52-week low/high is $0.071999996/$0.219999998.

chart

Kutcho Copper Corp. (KCCFF)

InvestorX, Junior Stock Review, Investors Hangout, The Prospector News, Mining & Energy, Wallet Investor, OTC Markets, Resource Stock Digest, Market Screener, 4-Traders, Stateside Report, Junior Mining Network, Stock Orange, Resource World, Dividend Investor, Stockhouse, Barchart, Stockwatch, and MarketWatch reported previously on Kutcho Copper Corp. (KCCFF), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Kutcho Copper Corp. concentrates on expanding and developing the Kutcho high grade copper-zinc project in northern British Columbia. The Company’s intention is to progress the Kutcho Project through feasibility and permitting to a positive construction decision. A resource development company, Kutcho Copper is headquartered in Vancouver, British Columbia (B.C.).

The Kutcho Copper Project is Kutcho’s 100 percent owned high grade copper-zinc development project in northern B.C. This Project is in a top tier mining jurisdiction with major mines and permitted projects in Tahltan and Kaska territories. Kutcho Copper has a Probable Reserve of 10.4 Mt grading 2.01% Cu and 3.19% Zn (2.92% CuEq).

The Kutcho Copper Project has a Mine Life of 12 years. Its Production Rate is 2,500 tpd. The Project has low risk potential to increase Mineral Reserves and substantially increase production capacity.

The Wheaton Precious Metals stream establishes a basis for a strong partnership and lessens financial risk of the Project. Furthermore, there is the potential for more discoveries via exploration. Kutcho Copper’s objective is to increase reserves from the present 10.4 Mt through existing resource conversion.

Kutcho Copper has launched MineHub Technologies, Inc. with a syndicate of industry partners. This includes a senior mining company, one of the world’s largest streaming companies, a global base and precious metals and concentrates trading company and an international financial institution providing banking services in the metals and mining industry. MineHub is a leading-edge technology company taking advantage of blockchain technology to develop a new generation of applications for the metals and mining industry.

Recently, MineHub Technologies and IBM announced a collaboration to use blockchain technology to help improve operational efficiencies, logistics and financing and decrease costs in the high-value mineral concentrates supply chain - from mine to end buyer. Kutcho Copper, Goldcorp, Inc., ING Bank, Ocean Partners USA, Inc. and Wheaton Precious Metals are working with mining technology company MineHub to build the new mining supply chain solution on top of the IBM Blockchain Platform.

In addition, Kutcho Copper also recently announced it appointed Mr. Michael Rapsch as Vice President of Corporate Communications. Mr. Rapsch has a decade of in-depth investor relations and corporate communications experience. Before joining Kutcho Copper he held the position of Vice President, Corporate Communications at SilverCrest Metals, Inc. for the last three years.

Kutcho Copper Corp. (KCCFF), closed Wednesday's trading session at $0.1342, up 31.5686%, on 21,000 volume with 9 trades. The average volume for the last 3 months is 15,593 and the stock's 52-week low/high is $0.096600003/$0.349900007.

chart

Creative Medical Technology Holdings, Inc. (CELZ)

Live Trading News, MarketWatch, Emerging Growth, Stockhouse, Bio Quick News, Capital Cube, OTC Markets, InvestorsHub, Canadian Insider, and 4-Traders reported earlier on Creative Medical Technology Holdings, Inc. (CELZ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Creative Medical Technology Holdings, Inc. (CMT) is a clinical stage stem cell company listed on the OTC Markets Group’s OTCQB. The Company’s focus is on Urology and Neurology using stem cell treatments. Since 2011, CMT and its affiliate company, Creative Medical Health, Inc., have concentrated on regenerative medical solutions for unmet Urological and Neurological needs.  The Company has a patent portfolio that encompasses all treatments.  CMT has its corporate office in Phoenix, Arizona.

The Company has formed CaverStem International LLC. This is a majority-owned subsidiary centered on commercializing stem cell therapy for erectile dysfunction to global physicians and their patients. CaverStem is offering the Caverstem™ technology to selected physicians in the United States that qualify according to CMT's criteria.

CMT has also established CerebroStem LLC. This majority-owned subsidiary focuses on developing stem cell therapies for brain injuries and neurodegenerative diseases. Its initial focus will be treating radiation induced brain damage.

Via its own research and collaborations with top academic institutions, CMT has acquired a pioneering stem cell (AmnioStem) and developed proprietary protocols. Moreover, the Company has built an extensive intellectual property (IP) portfolio, developed complete treatment offerings for erectile dysfunction (ED), and launched a 40-patient trial for ED at UCLA.  CMT is also making advances for treating stroke using its newly acquired amniotic fluid-based stem cell. 

AmnioStem is Amniotic fluid derived stem cell. The AmnioStem patent covers means to isolate, grow, and use amniotic fluid derived stem cells in a scalable and commercializable way. AmnioStem cells do not necessitate matching with the recipient, as one size fits all.

Recently, CMT  announced an update of its activities. Regarding CaverStem domestic activities, the Company is continuing marketing to physicians throughout the U.S. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and growing each month. CMT anticipates reaching financial self-sufficiency by revenues from sales this year.

Creative Medical Technology Holdings, Inc. (CELZ), closed Wednesday's trading session at $0.0024, up 100%, on 259,670,079 volume with 937 trades. The average volume for the last 3 months is 31,813,596 and the stock's 52-week low/high is $0.001/$0.039999999.

chart

GH Capital, Inc. (GHHC)

Penny Picks, OTC Markets, MarketWatch, Barchart, Stockopedia, Morningstar, and InvestorsHub reported on GH Capital, Inc. (GHHC), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

GH Capital, Inc. has developed an online payment gateway (ClickDirectPay) to process online wire transfer transactions for different online merchants, chiefly in Europe. GH Capital is a FinTech holding company and offers a going public process advisory. Formed in 2014, GH Capital has its head office in Miami, Florida. The Company lists OTC Markets’ OTCQB. 

GH Capital’s Financial Technology (FinTech) product is ClickDirectPay.com.  Customers using ClickDirectPay can do a bank transfer fast, easily, as well as securely with their personal online banking information. Upon using ClickDirectPay, the merchant receives a real time transaction confirmation pertaining to the successful bank transfer.

GH Capital’s goal is to expand with ClickDirectPay worldwide. To meet this objective, it is working on concepts of Blockchain and Cryptocurrency processing. 

Regarding the Company’s Capital Market Advisory Service, it guides and assists international companies from the U.S, Canada, Europe, and Asia to complete the whole going public process from the beginning. GH Capital’s mission is to help small and emerging growth companies to get through the complete IPO (Initial Public Offering) process without difficulties. 

GH Capital is also considering acquisitions. The Company stated that 2018 could also be a year of acquiring companies from the payment industry. This could speed up the process to establish ClickDirectPay as a one stop solution for Cryptocurrency processing.

Recently, GH Capital announced that its online payment service subsidiary, ClickDirectPay, announced the launch of ClickDirectPay's Express Coin Payments. This provides merchants the ability to accept many cryptocurrencies into a secure wallet.

GH Capital also recently announced that its online payment service subsidiary, ClickDirectPay expanded its cryptocurrency payment solution offerings to support Monero, Dash, Zcash and Verge. The addition of these coins brings the total support of ClickDirectPay to 8 cryptocurrencies enabling businesses to scale their reach in accepting payments in the world of cryptocurrencies.

ClickDirectPay is introducing new tools for merchants to easily start accepting cryptocurrencies. In June, the Company announced that its online payment service subsidiary, ClickDirectPay rolled-out new tools to its online merchants to be able to more easily and quickly accept cryptocurrency as payment.

GH Capital, Inc. (GHHC), closed Wednesday's trading session at $0.00338, up 40.8333%, on 6,487,066 volume with 59 trades. The average volume for the last 3 months is 13,316,269 and the stock's 52-week low/high is $0.001395/$0.059999998.

chart

A.I.S. Resources Limited (AISSF)

Wall Street Analyzer, Stockhouse, Barchart, Business Insider, The Street, YCharts, Morningstar, MarketWatch, InvestorsHub, GuruFocus, Stockwatch, and Penny Stock Hub reported on A.I.S. Resources Limited (AISSF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, A.I.S. Resources Limited established in 1967. The Company is managed by experienced, highly qualified professionals who have a long record of accomplishment of success in lithium exploration, production and capital markets. They identify and develop early stage projects globally that have strong potential for growth. A.I.S. Resources has its head office in Nassau, Bahamas. The Company also has a Canadian office in Vancouver, British Columbia.

A.I.S. Resources concentrates on developing significant lithium resource projects in Argentina’s world-renowned Lithium Triangle. The Company has two large projects, Chiron and Guayatayoc. The Chiron Project is 2,732 Ha. The Guayatayoc Project is 5,225 Ha. A.I.S. Resources also has its Vilama Project in the Lithium Triangle. Vilama is 2,500 Ha.

Guayatayoc is an approved borate mine. It encompasses all industrial minerals including lithium. Guayatayoc and Guayatayoc III are in Jujuy Province, 5 kilometers from the town of Abralaite in the Puna plateau. This property encompasses about 5,000 hectares of the Guayatayoc Salar that hosts favorable geology for lithium and boron, positioned adjacent to the El Aguillar mountain range, the source of lithium and boron.

The Chiron Project comprises four concessions in the Salar de Quirón in the Province of Salta, roughly 10 kilometers from the township of Pocitos. Very encouraging results from other, close by, explorers classifies the Chiron Project as having considerable prospectivity.

Recently, A.I.S. Resources Limited announced it was granted an exploration license for seismic and drilling at its Chiron project. This allows A.I.S to quickly progress to a TEM seismic program and then drilling immediately thereafter.

The Company entered into a contract with Quantec Geoscience Argentina S.A. to conduct a 19 point TEM (VES) seismic survey in early January 2018. This work will be completed by February 2018. Preliminary tenders have been received from several drilling companies for an eight hole program of 3,200 meters.

A.I.S. Resources also recently announced that seismic testing detected three distinct aquifers over a wide-ranging region at its Chiron Project in the Pocitos Salar, Salta Province, Argentina.

Mr. Phil Thomas, A.I.S. Resources’ Chief Operating Officer and Exploration Director stated: "This initial seismic data from Chiron based on the TEM geophysics strongly supports our case for acquiring these strategic concessions. Together with our Guayatayoc Project to the northwest in Jujuy province, where we've made excellent progress with our pilot plant production chemistry, A.I.S. is on track for a breakthrough year as an emerging new producer in the lithium brine space in Argentina."

A.I.S. Resources Limited (AISSF), closed Wednesday's trading session at $0.07, up 31.209%, on 15,000 volume with 1 trade. The average volume for the last 3 months is 23,339 and the stock's 52-week low/high is $0.025129999/$0.133239999.

chart

Provision Holding, Inc. (PVHO)

GrowthPennyStocks, Penny Stock General, Shiznit Stocks, HotStockProfits, PennyDoctor, Stock Beast, RedChip, PennyStockLocks.com, Epic Stock Picks, Equity Observer, Value Penny Stocks, Wolf of Penny Stocks, Small Cap Firm, OTCMagic, MicroCapDaily, and StockRockandRoll reported on Provision Holding, Inc. (PVHO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Provision Holding, Inc., by way of its subsidiary, focuses on the development and distribution of intelligent interactive three-dimensional (3D) holographic display technologies, software, and integrated solutions for consumer and commercial centered application. These are chiefly for advertising and product merchandising markets. The Company’s initial line of display systems has proven to be ideally suited for indoor and outdoor point-of-sale (PoS), merchandising, and PoS related advertising venues. Provision Interactive Technologies, Inc. is a subsidiary of Provision Holding. Provision Holding is based in Chatsworth, California.

Provision’s products include HoloVision displays and 3D Savings Center kiosks. These enable advertisers and customers to reach captive audiences in grocery stores, malls, convenience stores, gas stations, banks, as well as other retail sites. The Company’s proprietary 3D holographic display technologies give advertisers first-rate ability to direct customized content to a target audience.

Provision's 3D holographic display systems represent a unique technology. This technology provides the projection of full color, high-resolution videos into space detached from the screen, without any special glasses. The Company has completed the development and prototype of its latest 3D holographic display system, the HL50.

The HL50 is its largest Holovision™ product. The design of it is for exhibitions and special events. The HL50 uses Provision Interactive Technologies’ patented and award-winning 3D holographic technology. It comes complete. This includes a media player and the Company’s proprietary software, HoloSoft™. The HL50 can project visually stunning 3D holographic videos, detached from the screen, floating in space more than 40 inches outward.

Recently, Provision Interactive Technologies announced that the Company entered into a multi-year partnership agreement with Discount Drug Mart, Inc. This partnership agreement is to install Provision’s proprietary 3D Savings Center kiosks inside Discount Drug Mart stores. The agreement represents the next major retail partnership for Provision.

Prosperity Investments, under its Joyful ATM brand, has entered into an agreement with Provision Interactive Technologies to integrate its 3D holographic display and coupon redemption platform into Joyful ATMs to boost in-store engagement and purchases at point-of-sale (PoS).

Greater than 48,000 Joyful ATM units are planned to undergo deployment across the U.S. and in another 68 countries over the next 72 months, at locations including banks, retailers, convenience stores, gas stations, and government buildings. Via the partnership, the ATMs will project 3D holographic advertising messages to attract customers to the unit. Upon the customer approaching the unit, they can redeem coupons for the advertised products that can be used right away, driving enhanced PoS activity.

Provision Holding, Inc. (PVHO), closed Wednesday's trading session at $0.0032, even for the day, on 115,000 volume with 4 trades. The average volume for the last 3 months is 1,365,537 and the stock's 52-week low/high is $0.002499999/$0.0302.

chart

The QualityStocks Company Corner

City View Green Holdings Inc. (CSE: CVGR) (OTCQB: LRZZF)

The QualityStocks Daily Newsletter would like to spotlight City View Green Holdings Inc. (CVGR) (OTCQB: LRZZF).

City View Green Holdings (CSE: CVGR) (OTCQB: LRZZF), trading through the facilities of the Canadian Securities Exchange ("CSE") under the symbol "CVGR" today announced that it has commenced trading under the ticker symbol "LRZZF" on the OTCQB® Venture Market. Per the announcement, CVGR has applied to change its OTCQB® trading symbol and, upon FINRA approval, will release an update in the coming weeks. To view the full press release, visit: http://nnw.fm/2bpGt

City View Green Holdings Inc.'s (CSE: CVGR) (OTCQB: LRZZF) (formerly Icon Exploration Inc.) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an A6ccess to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.

Management

Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

City View Green Holdings Inc. (CSE: CVGR) (OTCQB: LRZZF), closed Wednesday's trading session at $0.088, even for the day. The average volume for the last 3 months is 34 and the stock's 52-week low/high is $0.072159998/$0.208299994.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Recent developments in gene therapy hold out hope for the treatment of a wide range of diseases, including fatal lung cancer. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is focused on using gene therapy to tackle lung cancer, developing new drugs that can be used alongside existing treatments.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Wednesday's trading session at $0.90, up 4.834%, on 21,257 volume with 43 trades. The average volume for the last 3 months is 29,206 and the stock's 52-week low/high is $0.640999972/$2.55999994.

Recent News

chart

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

Petroteq Energy (TSX.V: PQE) (OTC: PQEFF), a fully integrated surface oil sands mining oil company with proprietary technology, on Tuesday announced the issuance to an arm’s length lender of a US$480,000 principal amount (including a 20% original issue discount) unsecured convertible debenture, and warrants exercisable for up to 2,666,666 of the company’s common shares, each at US$0.15, for 12 months. To view the full press release, visit: http://nnw.fm/J7uXr.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PQEFF), closed Wednesday's trading session at $0.20399, up 7.3632%, on 146,930 volume with 40 trades. The average volume for the last 3 months is 213,494 and the stock's 52-week low/high is $0.112099997/$1.21765995.

Recent News

chart

Grapefruit Boulevard Investments Inc. (IGNG)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit Boulevard Investments Inc., the wholly owned subsidiary of Imaging3 Inc. (IGNG).

Grapefruit Boulevard Investments Inc. (IGNG), a Los Angeles based cannabis company which has been licensed by the state of California to both manufacture and distribute cannabis products in California since January 2018, has engaged Singer Lewak, LLP of Los Angeles to audit its financial statements. To view the full press release, visit: http://nnw.fm/9QIXm.

Grapefruit Boulevard Investments Inc., a California corporation (“Grapefruit”), as of May 31, 2019, is a wholly owned subsidiary of Imaging3 Inc. (OTC: IGNG), a Delaware corporation whose shares of $.001 par value common stock are publicly traded on the OTCMarkets OTCQB Market under the symbol “IGNG.” IGNG is subject to the reporting requirements of the Securities Exchange Act of 1934 and files annual and quarterly reports pursuant thereto. Grapefruit holds licenses originally issued by the State of California in January 2018 to both manufacture and distribute cannabis products. Grapefruit’s management now owns a controlling interest in IGNG which now owns 100% of Grapefruit’s outstanding shares. As a result, IGNG’s financial reports will consolidate both IGNG’s and Grapefruit’s balance sheet, statement of operation and statement of cash flows and IGNG and Grapefruit will be operated as a single company. IGNG intends to change its name to Grapefruit and to obtain a more appropriate trading symbol as soon as possible. Hereinafter the combined companies will be referred to as “Grapefruit” or the “Company.”

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds licenses to both manufacture and distribute cannabis products which were originally issued in January 2018 and is fully compliant with all applicable laws and regulations to operate its cannabis manufacturing and distribution businesses.

The company is well-focused on sourcing only the “best of the best” raw cannabis materials to create the highest quality, most-trusted and consistent recreational and medical cannabis products for its customers. Grapefruit is committed to ensuring class-leading quality by rigorously testing the purity and potency of its raw materials throughout the manufacturing process and distribution chain.

Grapefruit owns and operates its fully licensed and compliant ethanol extraction laboratory located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, California. The company’s extraction lab produces high quality, cannabis-derived distillate, also known as “honey oil,” from cannabis flower and “trim.” THC honey oil is one of base cannabis commodities which serves as the active ingredient in everything from infused edibles and tinctures/creams to the cartridges used in vapes and e-cigarettes. Honey oil often sells on the wholesale marketplace for thousands of dollars per liter, with pricing being dependent on quantity purchased, as well as other market factors such as the availability and cost of the underlying flowers and/or trim.

Grapefruit began its extraction operations in May 2019. Plans are in place to expand its honey oil production through the purchase of additional distillation equipment, which is expected to significantly increase the company’s production capacity by the fourth quarter of 2019. Grapefruit’s extraction lab is fully scalable and expansion will be built-out on a two-acre lot owned by Grapefruit at the Coachillin’ site adjacent to its current manufacturing and distribution operation.

Grapefruit selected the City of Desert Hot Springs for its cannabis extraction laboratory, because the city has created a friendly business environment for cannabis-based manufacturers, including incentives like the absence of taxes on cannabis oil production revenues. This affords Grapefruit a fundamental competitive market advantage over other Honey Oil producers.

The California cannabis regulatory scheme is unique in that it requires all cultivators (cannabis farms) and manufacturers (whether producing oils/distillates, infused edibles, tinctures creams or other cannabis products) to sell their products into the legal cannabis wholesale and retail markets exclusively through licensed distributors such as Grapefruit. Grapefruit initially obtained its California recreational and medicinal cannabis distribution license Jan. 4, 2018. In May 2019, Grapefruit was granted its provisional distribution license which is renewable annually, thereby cementing the regulatory foundation necessary to rapidly expand its distribution business.

Grapefruit’s distribution license affords it a twofold strategic advantage: first, to market and sell its own cannabis product lines to retailers throughout California; and second, to buy and resell bulk cannabis flowers and trim as well as all other legal cannabis products to properly licensed distributors and/or retailers throughout California.

The Coachillin’ Canna-Business Park, home to Grapefruit’s current operating facilities and adjacent two-acre parcel of land, is a 160-acre, self-contained legally mapped compound providing the Company with a fully permitted and serviced physical plant from which Grapefruit intends to establish a leading position in the booming California cannabis sector. The parcel was purchased by the Company prior to the Park’s full development, and the value of the land the Company owns has conservatively since doubled in value to over $2 million. Additional long-term benefits of the Coachillin’ compound include agricultural rates for power, which are currently $0.09 per kilowatt hour; the Park’s deep-water well that fully satisfies its need for water; and security expenses shared by all resident businesses. The Coachillin’ Park’s promoters also plan to position the Park, located only 10 miles north of rapidly growing uptown Palm Springs and less than 15 miles from the site of the Coachella and Stagecoach music festivals as a must-see canna-tourism destination.

Grapefruit’s ultimate goal is to become a vertically integrated, seed-to-sale cannabis and CBD product company serving the California market. Moreover, it plans to roll-out its product lines in other states, such as Nevada, Illinois, Oregon, Colorado and Washington. Grapefruit has plans to build a large, all-inclusive facility that will house a 50,000-square-foot-plus indoor grow canopy, a large extraction laboratory designed to extract both THC and CBD cannabinoids via non-volatile (ethanol) and volatile (butane) processes, a manufacturing space to produce Grapefruit’s vape lines and CBD products, an FDA-certified kitchen for the production of Grapefruit edibles and a distribution facility to sell all products into the entire cannabis market. The indoor grow canopy operation will be outfitted and operated to produce ultra-high-quality flowers and buds, some of which, along with the high-quality trim resulting from cleaning and maintaining the grow, will provide biomass necessary to feed the company’s extraction laboratory. Fueled by this hand cultivated biomass, Grapefruit’s lab will continuously produce pesticide and heavy metal-free world class honey oil to both serve as the active ingredient in all of Grapefruit’s branded and unbranded products and meet the projected ever-growing demand for high quality honey oil in the California market.

Grapefruit’s motto – A High You Can Trust – embodies its philosophy and ethos, reminding consumers of the company’s commitment to manufacturing, procuring and distributing only the highest quality all-natural cannabis flower, concentrates and related products that are free from pesticides, heavy metals and bacteria. Grapefruit will target its products to all recreational cannabis enthusiasts’ as continuous, consistent cannabis products. By relentlessly adhering to these policies Grapefruit intends to become the Titleist of the Cannabis industry, known for unwavering quality and consistency.

Grapefruit is managed by a team of experts possessing the experience, skill and resources required to succeed in the competitive cannabis marketplace. Founded by brothers Bradley Yourist, CEO, and Daniel Yourist, COO, Grapefruit has expanded to become a group of industry professionals sharing a passion for all things cannabis. Both the CEO & COO are attorneys licensed to practice law the State of California who possess expert cannabis licensing and regulatory expertise and experience, which will allow Grapefruit to deftly navigate the ever changing California regulatory landscape and apply for new cannabis licenses at reduced costs when necessary, rather than having to acquire licenses that are often overvalued and/or pay outside counsel to handle such matters.

Grapefruit also has its own line of cannabis-infused concentrates and edibles. Among the brands now in stores or soon to be launched are:

  • Rainbow Dreams is a new lifestyle brand designed specifically for the recreational cannabis marketplace. The Rainbow Dreams brand captures the anything goes party vibe of the 1970s by offering an array of cannabis products, such as a line of vape carts with unique cannabis strains combined with all-natural flavors for a superior no-burn experience. Rainbow Dreams fills an important niche in the marketplace as a top shelf quality product line that is competitively priced.
  • Sugar Stoned, which Grapefruit acquired in the winter of 2018, has always been a popular cannabis edibles brand which terminated operations when recreational cannabis became legal and required a license in California. Grapefruit purchased the Sugar Stoned brand in 2019 and it is now a Grapefruit portfolio brand consisting of a premium quality cannabis-infused gummy line with eight different flavors: blue raspberry, cherry, grape, peach, pineapple, sour apple, strawberry and watermelon. Grapefruit intends to expand the brand in the near future through the release of a variety of infused cookies.

Grapefruit Boulevard Investments Inc. (IGNG), closed Wednesday's trading session at $0.11, up 4.7619%, on 381,760 volume with 54 trades. The average volume for the last 3 months is 129,449 and the stock's 52-week low/high is $0.006095/$0.358999997.

Recent News

chart

Neutra Corp. (OTCQB: NTRR)

The QualityStocks Daily Newsletter would like to spotlight Neutra Corp. (NTRR).

Texas-based Neutra Corp. (OTCQB: NTRR) is expanding into hemp cultivation and purified hemp extract products. Its CEO, Sydney Jim, discussed the company’s operations and objectives in an exclusive interview with NetworkNewsWire (http://nnw.fm/7wSXR).

Neutra Corp. (OTCQB: NTRR) is an early-stage research and development company bringing modern healthy living solutions to a multi-billion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture – one where consumers are demanding access to products that promote health and stave off potential health dangers.

Neutra is concentrating on developing into a vertically integrated company able to cultivate, manufacture and distribute hemp-based cannabidiol (CBD) products. Hemp-based CBD consumer products generated sales of up to $390 million in 2018 with projections pointing to a $3 billion market by 2022, according to the Hemp Business Journal.

Neutra’s new broadened scope, which includes the commercialization of newer, more effective products, aims to capitalize on this worldwide boom. Our company is seeking new and exciting opportunities that can accelerate Neutra’s mission to bring these products to a wider demographic. Our work reflects a renewed dedication to supporting a better body, environment and life for people around the globe.

Acquisitions

  • Vivis – Neutra is expanding its market presence in the rapidly growing hemp-derived CBD market with a letter of intent to acquire Vivis, an emerging retail brand of hemp-based health and nutritional products. Vivis’ hemp-derived CBD products are third-party certified as contaminant-free and of consistent quality and potency. Consumers are increasingly looking for this certification when they buy hemp-based CBD products. With Vivis as the new retail face of Neutra, the company is expecting greater interest in its expanding portfolio of branded products moving to market.
  • J3 Holdings – The signing of a letter of intent to acquire J3 Holdings includes the company’s land and warehouse, as well as a license to cultivate hemp and refine it into usable forms. Neutra has concentrated its early efforts developing business networks and on developing hemp-based CBD products, including supplements and creams. The latest move will enable the company to grow its own hemp supply, giving it more control over the quality of its ingredients.

Partners

  • Surface to Air Solutions is the North American distributor of a patent-pending, water-based solution known as Purteq, a green technology that works similar to photosynthesis.
  • ZeroBlast uses a durable, non-toxic, anti-microbial solution to eliminate all contaminates and kill germs on contact for a period of up to 90 days.

Leadership

Neutra president and CEO Sydney Jim provides strong executive leadership, a network of business contacts and experience implementing solid corporate strategy. Jim has a proven track record of adding value for public company shareholders. He founded Global Visionary Investments where operational support is provided to seven different companies and their subsidiaries. Jim was also the CEO of First Titan Energy, a microcap public company where he was responsible for restructuring the corporate structure, deal sourcing, and leading the company in mergers and acquisitions.

Dr. Scott Cherry is the company’s sports performance medical advisor. He is an energetic physician executive with a passionate focus on health, performance and prevention. Dr. Cherry received emergency medical technician training in the U.S. Navy, a bachelor’s degree in chemistry from Florida State University, medical degree from Nova Southeastern University, and a master’s degree of public health from Uniformed Services University F. Edward Herbert School of Medicine. Dr. Cherry has honed his skills in a variety of medical and executive positions spanning the U.S. Army and Navy, several Fortune 500 corporations, and major health care facilities over the past 20 years.

Neutra Corp. (OTCQB: NTRR), closed Wednesday's trading session at $0.0029, up 26.087%, on 83,122,313 volume with 577 trades. The average volume for the last 3 months is 20,158,379 and the stock's 52-week low/high is $0.0012/$0.100000001.

Recent News

chart

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences (CSE: WLLW), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, on Tuesday announced its engagement of The Howard Group as its capital markets communications advisor. The engagement is for twelve months at a fee of $9,000 per month, effective August 15, 2019, and is renewable after six months. To view the full press release, visit: http://nnw.fm/pS53n

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Wednesday's trading session at $0.64, even for the day, on 318,800 volume with 56 trades. The average volume for the last 3 months is 73,305 and the stock's 52-week low/high is $0.529999971/$5.25.

Recent News

chart

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF)

The QualityStocks Daily Newsletter would like to spotlight Therma Bright, Inc. (OTC: THRBF).

Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF) today commented on the recent transaction between Aurora Cannabis (TSX: ACB) and a syndicate of Canadian banks. Per the update, the block trade was executed on September 3 after market close and resulted in the exchange of a total of 28.8 million shares, each at a negotiated price of $3.00. To view the full press release, visit: http://nnw.fm/7FXqq.

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical industry. The company’s effective, non-invasive and pain-free skin care is based on proprietary technology which has received Class II medical device status from the U.S. Food and Drug Administration.

Therma Bright’s portfolio includes products, devices and treatments that have both cosmetic and medicinal or therapeutic benefits, such as for relief of pain, itch and inflammation resulting from more than 20,000 types of insect and marine life bites and stings, including bees, wasps, hornets, mosquitos, black flies and jellyfish.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.

Products

The company currently has two products on the market and another in the research and development phase:

InterceptCS™ is a thermal therapy device for the treatment and prevention of cold sores caused by the herpes simplex Type 1 virus*. Symptoms typically include sores around the mouth and lips which InterceptCS™ treats by application of controlled topical heat with no risk of burning the skin. When used at the first sign of an oncoming cold sore application of InterceptCS™ can prevent symptoms from developing. Infrared energy and light from the device penetrate the skin killing cells infected with the virus.

InterceptCS™ is available without prescription and comprises a battery powered ergonomic hand-held unit and a disposable single-use treatment activator. Therma Bright has completed prototyping of multi-use activators for InterceptCS™. The company plans to bring to market 5, 10 or 20 multi-use activations at prices that will offer customers greater value than the current single-use activator.

The other Therma Bright product currently under development is TherOZap™, a next generation thermal therapy device powered by the company’s core technology, which is approved by the FDA as a Class II medical device for the relief of the symptoms of insect bites. Therma Bright is testing a new easier-to-use prototype of the device for effectiveness against Zika virus and other diseases carried by mosquitos. Once the technology proves effective, Therma Bright intends to seek regulatory approvals and extend the prototype enhancements to a new commercial version of TherOZap™.

Cannabis

Therma Bright is also conducting research and development on a unique thermal therapy device that would incorporate medical grade cannabis or cannabidiol (“CDB”) sourced from hemp as a cream or gel to provide relief of back, knee and other joint pain. In preparation, the company has incorporated a wholly owned subsidiary to hold any technology for use or application of cannabis. Once approvals are secured, the company plans to sell the device through licensed cannabis producers or retailers across Canada and in international markets where use of cannabis has been legalized. The company has initiated trademark and patent protection for its thermal therapy technology incorporating medical cannabis. Therma Bright has indicated it will seek an acquisition to help further development of this product.

Market Opportunity

A report by market intelligence firm Mordor Intelligence put the global cosmeceuticals market at a value of nearly US$47 billion in 2017 and projects it to be worth more than $80 billion by 2023, growing at a rate of almost 9.5 percent annually. Medical research estimates that somewhere between 20 percent and 40 percent of the population suffer occasional cold sore outbreaks. In Canada those figures would mean five to 10 million people, and in the U.S. some 40 million to 80 million, with recurring cold sores, representing a substantial potential market for Therma Bright.

Management

Rob Fia serves as Therma Bright chairman and CEO. Fia has extensive contacts in the investment community and the financial sector as well as knowledge of various Canadian stock exchange listing processes and requirements. His 18 years in the investment business has included equity research and advising promising early stage companies on corporate finance. Therma Bright CFO Victor Hugo is a senior financial analyst at Marrelli Support Services Inc., for which he provides CFO, accounting, regulatory compliance, and management advisory services to companies listed on the TSX, TSX Venture Exchange and other Canadian and US exchanges.

**Based on double blind placebo study, the InterceptCS™ is approved by Health Canada for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” The InterceptCS™ is not approved by the United States FDA or any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.

Therma Bright, Inc. (OTC: THRBF), closed Wednesday's trading session at $0.022, even for the day, on 10,000 volume with 1 trade. The stock's 52-week low/high is $0.009899999/$0.028999999.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF) today commented on the recent transaction between Aurora Cannabis (TSX: ACB) and a syndicate of Canadian banks. Per the update, the block trade was executed on September 3 after market close and resulted in the exchange of a total of 28.8 million shares, each at a negotiated price of $3.00. To view the full press release, visit: http://nnw.fm/7FXqq.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Wednesday's trading session at $2.22, off by 15.5894%, on 3,319,215 volume with 2,874 trades. The average volume for the last 3 months is 517,381 and the stock's 52-week low/high is $1.60699999/$7.89379978.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Drug bio-delivery technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched online commercial delivery of the cannabis industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format, making high-quality hemp oil with cannabidiol (CBD) readily available to meet the beverage infusion needs of consumers in the United States. Also today, NetworkNewsWire released a report highlighting the company which examines how, while effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the drug-delivery technology used and innovation in this space may have a huge impact on how successful a drug can be.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hmep-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Wednesday's trading session at $0.645, off by 1.0053%, on 65,489 volume with 58 trades. The average volume for the last 3 months is 75,325 and the stock's 52-week low/high is $0.600000023/$2.20000004.

Recent News

chart

Marijuana Company of America Inc. (MCOAD)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOAD).

Innovative hemp and cannabis corporation Marijuana Company of America (OTCQB: MCOA, MCOAD) today announced the official launch of its premium cannabis delivery service, VivaBuds, in California’s San Fernando Valley. The launch is a result of the company’s previously-announced 20% ownership interest acquisition of Natural Plant Extract of California (“NPE”) to establish a joint venture to create VivaBuds, a California marijuana delivery company offering customers a dynamic opportunity to purchase low-cost premium cannabis products directly from farmers using a “Tell a Friend” approach. To view the full press release, visit: http://nnw.fm/M4D9u.

Marijuana Company of America Inc. (OTC: MCOAD) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOAD), closed Wednesday's trading session at $0.26, off by 10.3448%, on 801,026 volume with 528 trades. The stock's 52-week low/high is $0.023/$2.13000011.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

VPR Brands LP (OTCQB: VPRB), a technology holding company whose assets include issued U.S. and Chinese patents for atomization-related products, including technology for medical marijuana vaporizers and electronic cigarette products and components, is positioned to benefit as the Southeast Asian medical market could soon start using medical marijuana for the treatment of its patients. This news was announced by Thailand Public Health Minister Anutin Charnvirakul, who is also the deputy prime minister of Thailand (http://nnw.fm/AqC5M). Also today, NetworkNewsWire released a report on the company detailing how VPR Brands continues to advance its own dedication to growth through an experienced management team that’s committed to unique brands and expanded distribution into the CBD vertical

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit?www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit?www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit?www.goldlinehemp.com?for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Wednesday's trading session at $0.1084, off by 1.0046%, on 639,845 volume with 71 trades. The average volume for the last 3 months is 96,367 and the stock's 52-week low/high is $0.033799998/$0.119999997.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: NABIF).

Based in Vancouver, Canada, Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: 71P) is targeting positive cash flow and strategic assets in the cannabis space, both in the United States and abroad. Nabis already has investments in Arizona, California, Michigan and Washington and is looking to expand its portfolio to include four to five more states in the next three to four months.

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: NABIF), closed Wednesday's trading session at $0.101949, off by 8.7296%, on 63,208 volume with 13 trades. The average volume for the last 3 months is 56,718 and the stock's 52-week low/high is $0.100100003/$0.791499972.

Recent News

chart

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions (OTCQB: SGSI), a leading single-source provider of next-generation communications network infrastructure and maintenance solutions, this morning announced that it has secured a key 3-year nationwide contract renewal with a tier-1 U.S. based telecommunications company. To view the full press release, visit: http://nnw.fm/eC45C.

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed Wednesday's trading session at $0.028, off by 11.9497%, on 426,333 volume with 36 trades. The average volume for the last 3 months is 197,851 and the stock's 52-week low/high is $0.014999999/$2.5999999.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint Inc. (OTCQB: SING) is pleased to announce the company will be presenting its latest product by Pure, a 100% American grown smokable Hemp Cigarette. In booth 5653, SinglePoint will be displaying the Pure product and showcasing it to major store chains among others at the show that draws over 23,000 attendees.Also today, the company was highlighted in an article examining how LinkResPet (OTC: LRSV) has made available its LYNKS CBD Pet Water, a joint venture with American Premium Water Corp (OTC: HIPH) on SingleSeed.com, a subsidiary of Singlepoint, Inc. (OTCQB: SING). Additionally, the company was featured in the 420 with CNW by CannabisNewsWire. A quarter of a million dollars is being handed by a U.S. federal agency to a biotech company so that research into how dangerous pesticides can be removed from several crops, including marijuana, can be done.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Wednesday's trading session at $0.0125, off by 0.793651%, on 2,623,018 volume with 108 trades. The average volume for the last 3 months is 5,484,233 and the stock's 52-week low/high is $0.009999999/$0.041000001.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.